Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

G. Jerusalem*, G. Mariani, E. M. Ciruelos, M. Martin, V. C. G. Tjan-Heijnen, P. Neven, J. G. Gavila, A. Michelotti, F. Montemurro, D. Generali, E. Simoncini, I. Lang, J. Mardiak, B. Naume, M. Camozzi, K. Lorizzo, S. Bianchetti, P. Conte

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1719-1725
Number of pages7
JournalAnnals of Oncology
Issue number9
Publication statusPublished - Sep 2016


  • advanced breast cancer
  • BMI
  • elderly
  • everolimus
  • hormone-receptor positive
  • stomatitis

Cite this